BioWorld Asia

May 25, 2011

View Archived Issues

Membrane Receptors Will Open Door to Drug Discovery

EMA Follows FDA Line on Huntexil Development Path

Oxford Biomedica's Parkinson's Drug Improves Motor Function

Spinnovator Raises $56M for New German Start-ups

Going Global: Takeda Paying $13.7B Cash for Nycomed

Shire Acquires Advanced BioHealing for $750M

Other News To Note

GenKyoTex's $20.4M Series C Funds NOX Inhibitor Progress

LONDON – GenKyoTex SA raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver proof of concept for the company's NOX enzyme inhibition technology. (BioWorld International) Read More

Evotec Shares Fall with Terminated Roche Alliance

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...